NorrDia Medical completes new financing round exceeding RMB 100 million to accelerate the development of a global full-category blood purification platform

NorrDia Medical has announced the completion of a new financing round exceeding RMB 100 million, led by Zhejiang Fuzhe Equity Investment Fund, with participation from Yongshan Fund, and continued follow-on investment from existing shareholder Hongsheng Capital. The proceeds from this financing round will be primarily used to support the ongoing integration and operation of the Bellco series of assets being advanced by NorrDia Medical, as well as to accelerate the regulatory filing and commercial rollout of its core products in both Chinese and international markets.

This marks the second external financing for NorrDia Medical within one year. In June 2025, the company completed a financing round of several tens of millions of RMB, led by Hongsheng Capital, with the funds primarily focused on the integration following the acquisition of the Nikkiso CRRT business. The significant scale increase of this current round signals that NorrDia Medical has formally transitioned from a single-line focus on acute critical care into a new stage of platform-based development, characterized by the synergistic advancement of both acute and chronic disease portfolios, driven by a dual-engine approach in both domestic and international markets.

NorrDia Medical is dedicated to the blood purification field and is rapidly building a full-category product portfolio through a merger and acquisition-driven strategy. The company completed the acquisition of Nikkiso's global CRRT business in early 2025, gaining access to a full series of acute critical care blood purification products and related therapies centered around the Aquarius system. The funds from this current round will primarily support the acquisition of Bellco, formerly the renal division of Medtronic, which will further complete the company's full-spectrum product portfolio covering chronic in-center dialysis (dialysis machines, dialyzers, dialysis consumables, and dialysate), as well as specialty therapies including HFR (endogenous reinfusion hemodiafiltration), PHF (paired hemodiafiltration with online pre- and post-dilution), plasma perfusion, and cytokine adsorption. The related product registration certificates cover more than 20 countries and regions, including the European Union, China, Canada, Russia, and Latin America.

Upon completion of the acquisition, NorrDia Medical will establish a comprehensive blood purification product system covering a full range of acute and chronic indications across both domestic and international markets, with the capability to operate an independent closed loop from equipment to consumables to replacement fluid. NorrDia Medical's core management team has extensive experience holding executive positions at world-leading blood purification companies, possessing mature capabilities in cross-border asset integration.